CaaMTech Secures $22 Million Series A Led by Noetic Fund to Push Psychedelic Drug Candidates into Human Trials

CaaMTech raised $22 million in a Series A led by Noetic Fund to advance its analytically pure psychedelic compound library toward human clinical trials, expand its leadership team, and support its cross-disciplinary research program.

More: GeekWire

No comments yet.